1 results
23 - Experimental models for demyelinating diseases
-
- By Jason M. Link, Portland Veterans Affairs Medical Center Oregon Health and Science University R&D-31 3710 SW US Veterans Hospital Rd Portland, OR 97239 USA, Richard E. Jones, Portland Veterans Affairs Medical Center Oregon Health and Science University R&D-31 3710 SW US Veterans Hospital Rd Portland, OR 97239 USA, Halina Offner, Portland Veterans Affairs Medical Center Oregon Health and Science University R&D-31 3710 SW US Veterans Hospital Rd Portland, OR 97239 USA, Arthur A. Vandenbark, Department of Neurology Tykeson Multiple Sclerosis Research Laboratory Veterans Affairs Medical Center Oregon Health and Science University Portland, OR 97239 USA
- Edited by Turgut Tatlisumak, Marc Fisher
-
- Book:
- Handbook of Experimental Neurology
- Published online:
- 04 November 2009
- Print publication:
- 05 October 2006, pp 393-410
-
- Chapter
- Export citation
-
Summary
Introduction
Multiple sclerosis (MS) is a demyelinating disease of the central nervous system (CNS) which manifests most commonly as weakness and sensory loss and is characterized by immune-mediated inflammation. Approximately 2.5 million individuals worldwide (400 000 in the USA) are afflicted with MS and among these, the disease is skewed toward Caucasians and females. The resultant economic burden caused by MS in the USA is approximately $20 billion. Superimposed on this cost is the personal burden of living with a debilitating condition for which there is no permanent cure and often no treatment of symptoms. MS is progressive in most patients and within 15 years of diagnosis, 70% of patients are unable to perform normal daily activities without assistance. The most frequently administered treatments (interferon (IFN)-β1a or IFN-β1b) for the most common disease course (relapsing–remitting MS) result in 30% fewer clinical exacerbations and can only delay onset of disability. Thus, researchers in autoimmunity and neurology are in pursuit of new treatments that can effectively and reliably halt or reverse progression of MS.
Establishing potential MS therapies requires an experimental animal model of the disease. The conventional animal model, experimental autoimmune encephalomyelitis (EAE), is a symptomatic and histologic recapitulation of MS based on a presumed etiology of autoimmune-mediated demyelination. In the earliest demonstrations of EAE, it was found that injections of brain or spinal cord extract could cause disease in primates and that addition of an immunological adjuvant eliminated the requirement for repeated injections and decreased the number of days until onset of symptoms.